Discover

ABUS
Arbutus Biopharma Corporation
4.84
10 x 3.53
17 x 4.84
bid
ask
+
0.11
2.33%
12:11 PM
timesize
Ytd0.62%
1y51.72%
4.75
day range
4.96
3.08
52 week range
5.10
Open4.79Prev Close4.73Low4.75High4.96Mkt Cap955.09M
Vol796.72KAvg Vol1.99MEPS0.83P/E5.83Forward P/E-9.35
Beta1.92Short Ratio6.50Inst. Own53.86%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg4.38200-d Avg4.421yr Est5.08

ABUS News

benzinga.com
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analys

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation s

Europe Clears First Flu/COVID Combo Shot From Moderna
benzinga.com
Europe Clears First Flu/COVID Combo Shot From Moderna

Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data s

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
benzinga.com
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursda

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopha

Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com
Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim

benzinga.com
Arbutus Biopharma's Imdusiran Receives FDA's Fast Track Designation To Treat Chronic Hepatitis B

Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinica

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
globenewswire.com
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatiti

Fast Track designation has the potential to facilitate development and accelerate FDA review of imdu

benzinga.com
Arbutus Biopharma Q4 EPS $(0.01) Beats $(0.03) Estimate, Sales $1.051M Miss $1.233M Estimate

Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analys

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of Dece

Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
benzinga.com
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars

Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor c

Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
Staar Surgical Posts Downbeat Q4 Results, Joins Webtoon Entertainment, Gitlab And Other Big Stocks M

Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305

Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
wsj.com
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant

The company will appeal to a federal circuit court to argue that it has limited liability due to its

benzinga.com
Roivant Sciences' Subsidiary, Arbutus Biopharma Sign $2.25B Settlement With Moderna To Resolve All U

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust l

Moderna Resolves Global Patent Litigation with Arbutus/Genevant
accessnewswire.com
Moderna Resolves Global Patent Litigation with Arbutus/Genevant

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
globenewswire.com
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
globenewswire.com
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Mo

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u

Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
seekingalpha.com
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts

Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creat

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
zacks.com
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know

Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the com

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Modern

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
globenewswire.com
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a poten

Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
zacks.com
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?

Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their se

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
zacks.com
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared

Arbutus (ABUS) Q2 Revenue Surges 529%
fool.com
Arbutus (ABUS) Q2 Revenue Surges 529%

Arbutus (ABUS) Q2 Revenue Surges 529%

Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
zacks.com
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Cons

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater C

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
globenewswire.com
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with La

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Gr

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensu

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
globenewswire.com
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to d

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
globenewswire.com
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure i

benzinga.com
Walmart To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday

benzinga.com
Earnings Scheduled For February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

benzinga.com
Earnings Scheduled For November 7, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

benzinga.com
Earnings Scheduled For August 3, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings

benzinga.com
Earnings Scheduled For May 4, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a

benzinga.com
Earnings Scheduled For March 2, 2023

Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at

benzinga.com
Earnings Scheduled For November 9, 2022

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

benzinga.com
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cance

Here's a roundup of top developments in the biotech space over the last 24 hours:

benzinga.com
Earnings Scheduled For August 4, 2022

  Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for

benzinga.com
Earnings Scheduled For May 5, 2022

  Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 849 stocks hit new 52-week lows.

benzinga.com
Earnings Scheduled For March 3, 2022

  Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly ea

benzinga.com
Mid-Morning Market Update: Markets Open Higher; G-III Apparel Earnings Beat Views

Following the market opening Wednesday, the Dow traded up 0.99% to 34,824.47 while the NASDAQ climbe

benzinga.com
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, I

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched

benzinga.com
Earnings Scheduled For November 4, 2021

  Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e

benzinga.com
60 Biggest Movers From Friday

Gainers

benzinga.com
41 Stocks Moving In Friday's Mid-Day Session

Gainers

benzinga.com
Earnings Scheduled For August 5, 2021

  Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report q

benzinga.com
Earnings Scheduled For May 5, 2021

  Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnin